콘텐츠로 건너뛰기
Merck
  • Simultaneous spectrophotometric determination of Cefpodoxime proxetil and Potassium clavulanate.

Simultaneous spectrophotometric determination of Cefpodoxime proxetil and Potassium clavulanate.

Hindustan antibiotics bulletin (2009-01-01)
Santosh V Gandhi, Upasana P Patil, Neelam G Patil
초록

Two accurate, precise, sensitive and economical procedures for simultaneous estimation of Cefpodoxime proxetil and Potassium clavulanate in tablet dosage form have been developed. The methods employed were absorbance correction method (I) and first order derivative spectroscopic method (II). The first method employs wavelength 288 nm for direct estimation of Cefpodoxime proxetil where Potassium clavulanate shows nil absorbance. Estimation of Potassium clavulanate is carried out after correction for absorbance of Cefpodoxime proxetil at 218 nm. The second method is based on first order derivative spectroscopy. Wavelengths 235.6 nm and 308.2 nm were selected for the estimation of the Potassium clavulanate and Cefpodoxime proxetil, respectively. Both the drugs obey Beer's law in the concentration range 5-50 microg/ml. The results of analysis have been validated statistically and by recovery studies. The percentage assay was found to be 99.54 +/- 0.285 for Cefpodoxime proxetil and 98.53 +/- 0.760 for Potassium clavulanate (Mean +/- SD) by method I and 99.93 +/- 0.270 for Cefpodoxime proxetil and 99.40 +/- 0.723 for Potassium clavulanate (Mean +/- S.D) by method II respectively.

MATERIALS
제품 번호
브랜드
제품 설명

USP
Cefpodoxime proxetil, United States Pharmacopeia (USP) Reference Standard
Cefpodoxime proxetil, European Pharmacopoeia (EP) Reference Standard
Cefpodoxime proxetil for impurity H identification, European Pharmacopoeia (EP) Reference Standard
Cefpodoxime proxetil for peak identification, European Pharmacopoeia (EP) Reference Standard